Rapid Determination of Serum Vascular Endothelial Growth Factor (VEGF) by a Fluorescence Immunochromatographic Assay

References

• Borgstrom, P., K. J. Hillan, P. Sriramarao, and N. Ferrara. 1996. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Research 56 (17):4032–9.
   PubMed Web of Science ®Google Scholar
• Cao, Y., P. Linden, J. Farnebo, R. Cao, A. Eriksson, V. Kumar, J. H. Qi, L. Claesson-Welsh, and K. Alitalo. 1998. Vascular endothelial growth factor C induces angiogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of America 95 (24):14389–94. doi:10.1073/pnas.95.24.14389.
   PubMed Web of Science ®Google Scholar
• Carmeliet, P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl 3):4–10. doi:10.1159/000088478.
   PubMed Web of Science ®Google Scholar
• Duh, E. J., J. K. Sun, and A. W. Stitt. 2017. Diabetic retinopathy: Current understanding, mechanisms, and treatment strategies. JCI Insight 2 (14):e93751. doi:10.1172/jci.insight.93751.
   PubMed Web of Science ®Google Scholar
• Ferrara, N. 2016. VEGF and intraocular neovascularization: From discovery to therapy . Translational Vision Science & Technology 5 (2):10. doi:10.1167/tvst.5.2.10.
   PubMed Web of Science ®Google Scholar
• Folkman, J. 1971. Tumor angiogenesis: Therapeutic implications. New England J. Med 285 (21):1182–6.
   PubMed Web of Science ®Google Scholar
• Fukumura, D., J. Kloepper, Z. Amoozgar, D. G. Duda, and R. K. Jain. 2018. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol 15 (5):325–40. doi:10.1038/nrclinonc.2018.29.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero, R., E. V. Cutsem, F. Rivera, J. Jassem, I. Gore, Jr, N. Tebbutt, F. Braiteh, G. Argiles, Z. A. Wainberg, R. Funke, et al. 2017. Randomized Phase II trial of parsatuzumab (Anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer. The Oncologist 22 (4):375–e30. doi:10.1634/theoncologist.2016-0133.
   PubMed Web of Science ®Google Scholar
• Gerber, H. P., and N. Ferrara. 2005. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Research 65 (3):671–80.
   PubMed Web of Science ®Google Scholar
• Hegde, P. S., J. J. Wallin, and C. Mancao. 2017. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Seminars in Cancer Biology 52 (Pt 2):117–24. doi:10.1016/j.semcancer.2017.12.002.
   PubMed Web of Science ®Google Scholar
• Jain, R. K. 2014. Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26 (5):605–22. doi:10.1016/j.ccell.2014.10.006.
   PubMed Web of Science ®Google Scholar
• Leung, D. W., G. Cachianes, W. J. Kuang, D. V. Goeddel, and N. Ferrara. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (New York, N.Y.) 246 (4935):1306–9. doi:10.1126/science.2479986.
   PubMed Web of Science ®Google Scholar
• Li, Y. W., L. Wang, G. Q. Zhang, H. Z. Xia, and J. P. Zou. 2015. Development and verification of chemiluminescent immunoassay for vascular endothelial growth factor. Chinese Journal of Biologicals 15 (9):938–42.
   Google Scholar
• Martínez-Castellanos, M. A., A. G. León, J. C. Romo-Aguas, and L. A. Gonzalez-Gonzalez. 2020. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series. Graefe's Archive for Clinical and Experimental Ophthalmology 258 (4):767–72. doi:10.1007/s00417-020-04605-y
   PubMed Web of Science ®Google Scholar
• Melincovici, C. S., A. B. Boşca, S. Şuşman, M. Mărginean, C. Mihu, M. Istrate, I. M. Moldovan, A. L.Roman, and C. M. Mihu. 2018. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Romanian Journal of Morphology and Embryology = Revue Roumaine de Morphologie et Embryologie 59 (2):455–67.
   PubMed Web of Science ®Google Scholar
• Siveen, K. S., K. Prabhu, R. Krishnankutty, S. Kuttikrishnan, M. Tsakou, F. Q. Alali, S. Dermime, R. M. Mohammad, and S. Uddin. 2017. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges . Current Vascular Pharmacology 15 (4):339–51. doi:10.2174/1570161115666170105124038.
   PubMed Web of Science ®Google Scholar
• Viallard, C., and B. Larrivée. 2017. Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis 20 (4):409–26. doi:10.1007/s10456-017-9562-9.
   PubMed Web of Science ®Google Scholar
• Xu, W. W. 2010. Evaluation index for in vitro diagnostic products (IVD) during R&D. Journal Molecular Therapy 2 (2):140–4.
   Google Scholar